Redefining Preclinical Development with Multimodal Patient-First Platform
Redefining Preclinical Research with Comprehensive Patient-First Technology
CaleoBio’s Patient-Derived Organ-Dish Platform Sets the Standard
for Predictive, Scalable Drug Development.
CaleoBio’s Patient-Derived Organ-Dish Technology Provides a Reliable, Scalable Platform for Drug Development.
Guiding Treatment with Data, Not Doubt.
Conventional approaches fail to reliably predict treatment outcomes. By combining advanced preclinical modeling with human-first data, we reduce uncertainty and accelerate effective therapies.
Pioneering Advanced Preclinical Models.
Unlike traditional preclinical models with critical gaps in emulating human physiology, our next-generation technology integrates epithelial, immune and stromal cells to replicate human diseases.
Eliminating Uncertainty, Elevating Care.
CaleoBio’s patient-first models equip partners with insights to make informed decisions. By bridging lab discoveries to clinical success, we accelerate advanced therapies, ensuring faster delivery to patients.
Precision Medicine, Powered by Al
By integrating CaleoBio’s patient-first Organ-Dish platform with scalable, AI-driven analytics, we enable drug development teams to make, better-informed discovery and development decisions.
From Tissue Samples to Breakthroughs
Bridging the Gap between
Preclinical Models
and
Clinical Outcome
Predicting Success. Preventing Failure. Improving Lives.
We advance clinically relevant innovation and facilitate the delivery of effective treatments to patients who need them most worldwide.
Advance Drug Development with Us —
Scalable, Validated Approach
Together, we set human biology as the early benchmark for decision-making, before programs reach the clinic and costs escalate.